Prescription medicine
Eravacycline Brand names: Xerava
Eravacycline (Xerava) is a prescription medicine with an FDA approval on record since 2018. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the eravacycline FDA label on DailyMed (effective March 31, 2025, Tetraphase Pharmaceuticals, Inc.); the NDA 211109 record on Drugs@FDA; every eravacycline label on DailyMed.
Highlights of the record
FDA label of March 31, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageXERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra‑abdominal infections in patients 18 years of age and older.
Forms and strengths
- 50 mg
- 100 mg
Injection (powder) (lyophilized) for solution.
On the market
- Earliest approval on file
- August 27, 2018 Xerava, Tetraphase Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- October 19, 2037 Xerava injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 243 through July 30, 2026
What is eravacycline used for?
From the label: indications and usageXERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra‑abdominal infections in patients 18 years of age and older. ( 1.1 ) Limitations of Use XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI). ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. […]
FDA pharmacologic class: Tetracycline-class Antibacterial.
Source: FDA drug label (Xerava), Tetraphase Pharmaceuticals, Inc., effective March 31, 2025 (SPL set a4b188d4-f467-470c-ad7b-25ffbdd8862a), via openFDA; the full label on DailyMed
Is there a generic for eravacycline (Xerava)?
No generic eravacycline is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 4 patents for Xerava injection: the compound patent runs to October 19, 2037. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2018 earliest approval on file
- 2037 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the eravacycline label say about other medicines?
The eravacycline label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Tetracycline | warnings and precautions | A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hours. |
Source: FDA drug label (Xerava), Tetraphase Pharmaceuticals, Inc., effective March 31, 2025 (SPL set a4b188d4-f467-470c-ad7b-25ffbdd8862a), via openFDA; the full label on DailyMed
What do FAERS reports show for eravacycline?
The FDA Adverse Event Reporting System holds 243 reports that list eravacycline among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 43 are coded as a death and 68 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other tetracycline-class antibacterials
- the pharmacologic class, with prices and generics
- Eravacycline side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other